List view / Grid view
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...
9 November 2012 | By GlaxoSmithKline
Results from ongoing Phase III clinical trial announced...
9 November 2012 | By Novo Nordisk
“The positive vote from the Advisory Committee marks an important step..."
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
8 November 2012 | By Novartis
Update on leading R&D pipeline...
8 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…
8 November 2012 | By Merck
Merck announced that the NDA for suvorexant has been accepted for standard review...
8 November 2012 | By FOSS NIRSystems Inc.
FOSS NIRSystems, Inc. has introduced Vision 3.60. Vision is a software package specifically designed for use with the FOSS NIRSystems NIR laboratory & process analyzers...
8 November 2012 | By Merck
The Regenstrief Institute and Merck have signed a five-year agreement...
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
7 November 2012 | By Novartis
RELAX-AHF study met one of its two primary endpoints...
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
6 November 2012 | By
Gains innovative research platform-bacTRAP technology and adds novel CNS programs...
5 November 2012 | By
To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C...
